Антифосфолипидный синдром - часть 82

333

idiopathic antiphospholipid syndrome. Lupus
2002; 11: 208—214.

104. Roman MJ, Shanker BA, Loschin M, et

al. Accelerated atherosclerosis in systemic lupus
erythematosus: clinical correlations and time
dependency. Arthritis Rheum 2002; (Suppl): 57,
40 (abst).

105. Font J, Jimenez S, GarciaCriado A, et al.

Atherosclerosis in SLE is associated with accu
mulative disease damage but not with traditional
vascular risk factors. Arthritis Rheum 2002;
(Suppl.): 58 (42 abst).

106. RomeroDiaz J, BarraganCampos H,

Romero C, et al. Atherosclerotic vascular disease in
systemic lupus erythematosus (SLE). Yearly pro
gression of the carotid intimamedia thickness in the
inception cohort. ACR/ARHP Annual Scientific
Meeting October 24—28, 2003; 896 (abst). 

107. Theodoridou A, Bento L, Q`Cruz DP, et al.

Prevalence and associations of an abnormal
anklebrachial index in systemic lupus erythe
matosus; a pilot study. Ann Rheum Dis 2003; 62:
1199—1203.

108. Sella EM, Sato EI, Barbieri A. Coronary

artery angiography in systemic lupus erythemato
sus patients with abnormal myocardial perfusion
scintigraphy. Arthritis Rheum 2003; 48: 3168—
3175.

109. Atar S, Jean DS, Siegel RJ. Mitral annual

calcification: a marker of severe coronary artery
disease in patients under 65 years old. Heart
2003; 89: 161—164.

110. Rajamannan NM, Gersh B, Bonow RO.

Calcific aortic stenosis: from bench to bedside —
emerging clinical and cellular concept. Heart
2003; 89: 801—805.

111. Novard GM, Griffin BP. Calcific aortic

stenosis: another face of atherosclerosis. Clev Clin
J 2003; 70: 471—478.

112. Molad Y, LevinLaina N, Vaturi M, et al.

Increased prevalence of heart valve calcification
in patients with systemic lupus erythematosus: a
window to premature atherosclerotic vascular
morbidity. ACR/ARHP Annual Scientific Me
eting October 24—28, 2003; 895 (abst). 

113. Petri M, Roubenoff R, Dallal GE, et al.

Plasma homocystein as a risk factor for athero
thrombotic events in systemic lupus erythemato
sus. Lancet 1996; 348: 1120—1124.

114. Tam LS. Fan B, Li EK, et al. Patients

with systemic lupus erythematosus show increased
platelet activatiоn and endothelial dysfunction
induced by acute hyperhomocysteinemia. J
Rheumatol 2003; 30: 1479—1484.

115. Kabakov AE, Tertov VV, Saenko VA, et al.

The atherogenic effect of lupus sera systemic lupus
erythematosusderived immune complexes stimu
lated the accumulation of cholesterol in cultured
smoth muscle cellsfrom human aorta. Clin
Immunol Immunopathol 1992; 63: 214—220. 

116. Garrido JA, Peromingo JAD, Sesma P, Pia

G. More about the link between thrombosis and
atherosclerosis in autoimmune disease: trigli
cerides and risk for thrombosis in patients with
antiphospholipid antibodies. J Rheumatol 1994;
21: 2394.

117. Jurado M, Paramo JA, GutierrezPimentel

M, et al. Fibrinolityc potential and antiphospho
lipid antibodies in systemic lupus erythematosus
and other connective tissue disorders. Thromb
Haemost 1992; 68: 516—520.

118. Yamazaki M, Asakura H, Jokaji H, et al.

Plasma levels of lipoprotein (a) are elevated in
patients with antiphospholipid antybody syn
drome. Thromb Haemost 1994; 71: 424—427.

119. Nassonov E, Baranov A, Kovaliov V.

Von Willebrand factor antigen and antiphos
pholipid antibodies in systemic lupus erythe
matosus. Clin Exp Rheumatol 1994; 12 (Suppl
11): 97 (abst).

120. George J, Harats D, Shoenfeld Y, et al.

Induction of early atherosclerosis in LDL receptor
deficient moce immunized with beta 2 glycopro
tein I. Circulation 1998; 15: 1108—1115.

121. Afek A, George J, Shoenfeld Y, et al.

Enhanced atherosclerosis in apoE deficient mice
by immunization with 

β

2

glycoprotein I. Path

obiology 1999; 67: 19—25.

122. George J, Harats D, Gilburd B, et al.

Adoptive transfer of 

β

2

glycoprotein Ireactive

lymphocytes enhanced early atherosclerosis in
LDL receptor deficient mice. Circulation 2000;
102: 1822—1827.

123. George J, Harats D, Gilburd B, et al.

Immunolocalisation of 

β

2

glycoprotein I (apoli

poprotein H) to human atherosclerotic plaques:
potential implications for lesion progression.
Circulation 1999; 99: 2227—2230.

ГЛАВА 12. Атеросклеротическое поражение сосудов при системной красной волчанке и АФС

Насонов Е.Л. Антифосфолипидный синдром

334

124. Harats D, George J. 

β

2

glycoprotein I and

atherosclerosis. Curr Opin Lipidol; 2001; 12:
543—546.

125. Aho K, Vaarala O, Tenkanen L, et al.

Antibodies binding to anionic phospholipids but
not to oxidized lowdensity lipoprotein are associ
ated with thrombosis in patients with systemic
lupus erythematosus. Clin Exp Rheumatol 1996;
14: 499—506. 

126. Amengual O, Atsumi T, Khamashta MA,

et al. Antibodies against oxidized lowdensity
lipoprotein(oxLDL) in 107 patients with
antiphospholipid syndrome.(APS). Arthritis
Rheum 1996; 39 (Suppl.): 96.

127. Vaarala O, Alfthan G, Jauhiainen M,

LeirisaloRepo M, et al. Crossreaction between
antibodies to oxidised lowdensity lipoprotein and
cardiolipin in systemic lupus erythematosus.
Lancet 1993; 341: 923—925.

128. Vaarala O, Puurunen M, Lukka M, et al.

Affinitypurified cardiolipinbinding antibodies
show heterogeneity in their binding to oxidised
lowdensity lipoprotein. Clin Exp Immunol 1996;
104: 269—274.

129. Насонов ЕЛ, Попкова ТВ, Ефремов ЕЕ,

и соавт. Антитела к окисленному липопро
теину низкой плотности при системной
красной волчанке: связь с антителами к фос
фолипидам. Клин. медицина, 1997; 9: 49—52.

130. Romero FI, Amengual O, Atsumi T, et al.

Arterial disease in lupus and secondary antiphos
pholipid syndrome: association with anti

β

2

gly

coprotein I antibodies but not with antibodies
against oxidized lowdensity lipoprotein. Br J
Rheumatol 1998; 37: 883—888.

131. Horkko S, Miller E, Dudl E, et al. Anti

phospholipid antibodies are directed against epi
topes of oxidized phospholipids. Recognition of
cardiolipin by monoclonal antibodies to oxidized
low density lipoprotein. J Clin Invest 1996; 98:
818—823.

132. Horkko S, Olee T, Mo L, et al. Anticar

diolipin antibodies from patients with the
antiphosphlipid antibody syndrome recognize epi
tope in both 

β

2

glycoprotein I and oxidized low

density lipoprotein Circulation 2001; 103: 941—
946.

133. Mizutani H, Kurata Y, Kosugi S, et al.

Monoclonal anticardiolipin autoantibodies estab

lished from the (New Zeland WhiteXBXSB)F1
mouse model of antiphospholipid syndrome cross
reaсt with oxidized lowdensity lipoprotein.
Arthritis Rheum. 1995; 38: 1382—1388.

134. Matsuura E, Kobayashi K, Kasahara J, et

al. Oxidized autoantigens in atherosclerosis. In.
Atherosclerosis and autoimmunity Ed. Y
Schoenfeld, D. Harats, G Wick. Elsevier 2001;
143—150.

135. Kobayashi K, Kishi M, Atsumi T, et al.

Circulating oxidized low density lipoproteins
forms complexes with 

β

2

glycoprotein I: implica

tions as an atherogenic autoantigen. JLR 2003;
M200329—LR200.

136. Arfos L, Lefvert AK. Enrichment of anti

bodies against phospholipid in circulating immune
complex (CIC) in the antiphospholipid syndrome
(APLS), Clin Exp Imunol 1997; 108: 47—51.

137. Wu R, Huang YH, Elinder LS, Frostegard

J. Lysophosphatidylcholine is involved in the
antigenicity of oxidized LDL. Ather Thromb Vasc
Biol 1998; 18: 626—630.

138. Wu R, Svennungsson E, Gunnatsson I,

etal. Antibodies against lysophosphatidylcholin
and oxidase LDL in patients with SLE. Lupus
1999; 8: 142—150.

139. Elinder LS, Dumitresku A, Larson P, et

al. Expression of phospholipasa A

2

isoforms in

human normal and atherosclerotic arterial
wall. Arter Thromb Vasc Biol 1997; 17: 2257—
2263.

140. Pruzanski W, Goulding NJ, Flower RJ, et

al. Circulating group II phospholipasa A

2

activity

and antilipocortin antibodies in systemic lupus
erythematosus. Correlative study with disease
activity. J Rheumatol 1994; 21: 252—257.

141. Forte TM, McCall MR. The role of

apolipoprotein Alcontaning lipoproteins in
atherogenesis. Curr Opin Lipidol 1994; 5: 354—
364.

142. Hyka N, Dayer JM, Modoux C, et al.

Apolipoprotein AI inhibits the production of
Interleukin1 bets and tumor necrosis factor
alpha by blocking contactmediated activation of
monocytes by T lymphocytes. Blood 2001; 97:
2381—2389.

143. Merril JT, Weinstein A, Dinu A, et al.

Antibodies to apolipoprotein A1 in lupus popula
tion: crossreactivity with antibeta2 glycopro

335

tein1. Arthritis Rheum 1996; 39 (Suppl): 93
(abst).

144. Dinu AR, Merrill JT, Shen C, et al.

Frequency of antibodies to the cholesterol trans
port protein apolipoprotein A1 in patients with
SLE. Lupus 1998; 7: 355—380.

145. Abe H, Tsuboi N, Suzuki S, et al. Anti

apolipoprotein AI antibody: characterization of
monoclonal autoantibodies from patients with
systemic lupus erythematosus. J Rheumatology
2001; 28: 990—995.

146. Alves JD, Kumar S, Isenberg DA.

Crossreactivity between anticardiolipin,
antihighdensity lipoprotein and anti
apolipoprotein AI IgG antibodies in patients
with systemic lupus erythematosus and primary
antiphospholipid syndrome. Rheumatology
2003; 42: 893—899.

147. Reichlin M, Fesmire J, QuinteroDelRio

AI, et al Autoantibodies to lipoprotein lipase and
dislipidemia in systemic lupus erythematosus.
Arthritis Rheum 2002; 46: 2957—2963.

148. Romero FI, Atsumi T, Tinahones FJ, et al.

Autoantibodies against malodialdehydemodified
ipoprotein(a) in antiphospholipid syndrome.
Arthritis Rheum 1999; 42: 2606—2611.

149. Ames PRJ. Antiphospholipid antibodies,

thrombosis and atherosclerosis in systemic lupus
erythematosus: a unifying "membrane stress syn
drome" hypothesis. Lupus 1994; 3: 371—377.

150. Violi F, Micheletta F, Iuliano L. Oxidant

stress in SLE patients: relationship to atheroscle
rosis. In Atherosclerosis and autoimmunity. Ed Y.
Shoenfeld, D. Harrats and G. Wick. Elseiver.
2001; 273—278.

151. Ames PRL, Alves J, Murat L, et al. Oxi

dative stress in systemic lupus erythematosus and
allied conditions with vascular involvment.
Rheumatology (Oxford) 1999; 38: 529—534.

152. Ferro D, Pittoni V, Quintarelli C, et al.

Coexistence of antiphospholi[id antibodies and
endothelial perturbations in systemic lupus ery
thematosus with ongoing prothrombotic state.
Circulation 1997; 95: 1425—1432.

153. Iuliano L, Practico D, Ferro D, et al.

Enhanced lipid peroxidation in patients positive
for aPL. Blood 1997; 90: 3931—3995.

154. Ames PRJ, NouroozZadech J, Tomasino

C, et al. "Oxidative stress" in primary antiphos

pholipid syndrome. Thrombosis Haemostasis
1998; 79: 447—449.

155. Ames PR, Alves J, Murat I, Isenberg DA.

NouroozZadeh J. Oxidative stress in systemic
lupus erythematosus and allied conditions with
vascular involvement. Rheumatology (Oxford)
Jun 1999; 38 (6): 529—34.

156. Practico D, Ferro D, Iuliano L, et al.

Ongoing prothrombotic state in patients with
antiphospholipid antibodies: a role for increased
lipid peroxidation. Blood 1999; 93: 3401—3407.

157. Martinuzzo ME, Forastiero RR, Kordich

L, Carreras LO. Increased lipid peroxidation
correlates with platelet activation but not with
marker of endothelial cell and blood coagulation
activation in patients with antiphospholipid anti
bodies. Br J Haematol 2001; 114: 845—851.

158. Ames PRJ, Tommasino C, Alves J, et al.

Antioxidant susceptibility of pathogenic pathway
in subjects with antiphospholipid antibodies: a
pilot study. Lupus 2000; 9: 688—659.

159. Durrington PN, Mackness B, Maskness

NI. Paraoxanase and atherosclerosis. Arterioscler
Thromb Vasc Biol 2001; 21: 473—480.

160. Lambert M, Boullier A, Hachulla E, et al.

Paraoxonasa activity is dramatically decreased in
patients positive for anticardiolipin antibodies.
Lupus 2000; 9: 299—300.

161. Alves JD, Ames PJR, Donohue S, et al.

Antibodies to highdensity lipoprotein and beta2
glycoprotein I are inversely correlated with
paraoxonase activity in systemic lupus erythe
matosus and primary antiphospholipid syndrome.
Arthritis Rheum, 2002; 46: 2686—2694.

162. Lambert M, Helbecque N, Martin F, et al.

Evidence of paraoxanase polymorphism (Gln192
Arg) in patients with antiphospholipid syndrome.
AСR 66

th

Annual Scientific Meeting October 25—

29, 2002; 539 (abst).

163. Alves JD, Mason L, Ames PRL, et al.

Anticardiolipin antibodies are associated wirh
decreased plasma nitric oxide and paraoxanase
activity in a murine model of antiphospholipid
syndrome. ACR/ARHP Annual Scientific
Meeting October 24—28, 2003; 334 (abst). 

164. Reiser H, Stadecker MJ. Costimulatory B7

molecules in the pathogenesis of infectious and
autoimmune diseases. N Engl J Med 1996; 335:
1369—1377.

ГЛАВА 12. Атеросклеротическое поражение сосудов при системной красной волчанке и АФС

Насонов Е.Л. Антифосфолипидный синдром

336

165. Kalled SL, Cutler AH, Datta SK, Thomas

DW. AntiCD40 ligand antibody treatment of
SNF1 mice with established nephritis: preserva
tion of kidney function. J Immunol 1998; 160:
2158—2165.

166. Huang W, Sinha J, Newman J, et al. The

effect of antiCD40 ligand antibody on B cells in
human systemic lupus erythematosus. Arthritis
Rheum 2002; 46: 1554—1562.

167. Kato K, SantanaSahagun E, Rassenti

LZ, et al. The soluble CD40 ligand (sCD154) in
systemic lupus erythematosus J Clin Invest 1999;
104: 974—955.

168. Aringer M, Smolen JS. Complex cytokine

effect in a complex autoimmune disease: tumor
necrosis factor in systemic lupus erythematosus.
Arthritis Res Ther 2003; 5: 172—177.

169. Samsonov MU, Tilz GP, Nasonov E,

Egorova O, Balabanova RM, Nassonov, Wachter
H, Fuchs D. Serum soluble markers of immune
activation and disease activity in systemic lupus
erythematosus. Lupus 1995; 4: 29—32.

170. Бородин АГ, Баранов АА, Клюквина НГ,

Абайтова НЕ, Насонов ЕЛ. Клиникотогене
тическое значение фактора некроза опухоли
альфа при системной красной волчанке. Тера
певт. архив, 2002; 5: 32—35.

171. Maury CP, Teppo AM. Tumor necrosis

factor in serum of patients with systemic lupus ery
thematosus. Arthritis Rheum 1989; 32: 146—150.

172. StudnickaBenke A, Steiner G, Petera P,

Smolen JS. Tumor necrosis factor alpha and its
soluble receptor paralled clinical disease and

autoimmune activity in systemic lupus erythe
matosus. Br J Rheumatology 1996; 35: 1067—
1074.

173. Gabay C, Cakir N, Moral F, et al. Circu

lating levels of tumor necrosis factor soluble
receptor in systemic lupus erythematosus are sig
nificantly higher than in other rheumatic disease
and crrelate with disease activity. J Rheumatol
1997; 24: 303—308.

174. Aringer M, Feierl E, Steiner G, et al.

Increased bioactive TNF in human systemic lupus
erythematosus: associations with cell death.
Lupus 2002; 11: 102—108.

175. Bertolaccini ML, Atsumi T, Lanchbury

JS, et al. Plasma tumor necrosis factor alpha level
and —238*A promoter polymorphism in patients
with antiphospholipid syndrome. Thromb
Haemost 2001; 85: 193—194.

176. Frostegard J, Guozhong F, JensenUrstad

K, et al. TNFalfa — a link between inflamma
tion and dyslipoproteinemia in SLE patients with
cardiovascular disease. 2002 EULAR Annual
Congress of Rheumatology, june 12—14, OP0095
(abst). 

177. Fei GZ, Svenungson E, Padyukov L,

Frostegard J. The functional role of — 1087 IL10
polymorphism in the development of atherosclero
sis in female SLE patients. ACR 66th Annual
Scientific Meeting October 25—29, 2002; 6
(abst).

178. Hahn BH. Systemic lupus erythematosus

and accelerated atherosclerosis. New Engl J Med
2003; 349: 2379—2380.